Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novanight is a multi-ingredient dietary supplement formulated to improve sleep quality and reduce the time required to fall asleep. Originally developed by Sanofi and currently marketed by Opella Healthcare, the product features a "Triple Action" formulation. Its primary active components include melatonin (1 mg), which acts as an agonist at melatonin receptors to regulate the circadian rhythm, and a blend of botanical extracts: passionflower (Passiflora incarnata), California poppy (Eschscholtzia californica), and lemon balm (Melissa officinalis). The formulation is often supplemented with vitamin B6 to support normal psychological function. Novanight is available in oral formats such as tablets and sachets and is positioned within the consumer healthcare market for adults experiencing transient sleep disturbances.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Novanight.